Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
Read Article
Best of 2024: 13 Risk Factors for RA-associated Interstitial Lung Disease
Interstitial lung disease (ILD) is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%.
Read Article
State Update @ACRheumDC
No executive level changes, some state legislative flips
Political changes will likely lead to more state legislative healthcare legislation
- In the works for PBM reform, copay accum, prior auth/Step, reprod healthcare
@RheumNow #ACR24 https://t.co/94KyHU0Blr
Links:
Eric Dein @ericdeinmd( View Tweet )
@LennMcD @ACRheumDC
Current congress (118th) - very tight margins, paralyzed by the ‘24 elections. Now in lame duck
Many ACR policies made into bills - PA, step rx, copay accumulator, workforce, loan repayment, incr Rx transparency
Needs to be passed into law
@RheumNow #ACR24 https://t.co/1elEUiUAmh
Eric Dein @ericdeinmd( View Tweet )
Early RA Journey - Patient Perspectives and Uncertainties
Canadian early RA (ERA) patients were interviewd to depict their perspectives from onset and diagnosis to referral and care. This report highlights the importance of patient pain and primary care physician (PCP) intake… https://t.co/gwNL7iZIT5 https://t.co/SL0Jw0H8f6
Dr. John Cush @RheumNow( View Tweet )
ACR’s Run at Goliath (PCPs) (5.31.2024)
Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?
Read Article
13 Risk Factors for RA-associated Interstitial Lung Disease
Interstitial lung disease (ILD) is the most widespread and fatal pulmonary complication of rheumatoid arthritis (RA). A recent metanalysis shows the pooled prevalence of RA-ILD was approximately 18.7%.
This systematic review included 56 studies with 11,851 RA-ILD patients. The
Read Article
Methotrexate + pegloticase increases response rates in gout
In abstract 0001 presented at ACR22 Convergence, researchers presented 12-month data from a randomized double-blind placebo-controlled trial of pegloticase with or without MTX.
Read Article
